icon-folder.gif   Conference Reports for NATAP  
 
  46th Annual ICAAC
Interscience Conference on Antimicrobial
Agents and Chemotherapy
Sept 27-30, 2006, San Francosco
Back grey_arrow_rt.gif
 
 
 
Safety, Tolerability & Efficacy of Abacavir/Lamivudine/Zidovudine vs. Atazanavir & Lamivudine/Zidovudine in Antiretroviral Naive Subjects
 
 
  ESS100327: ACTION Study
 
Reported by Jules Levin
ICAAC Sept 27-30, 2006, San Francisco
 
There were criticisms of this study raised at ICAAC saying that the two arms of this study were alternative regimens therefore neither therapy provided in the study was the standard of care recommended by the guidelines for first choice in starting HAART. The critics asked if study enrollees were screened to see if they could or would tolerate the HHS recommended firstline therapies before giving them two alternative therapies.
 
Authors; Kumar PN, Salvato P, DeJesus E, LaMarca A, Patel P, Sutherland-Phillips D, McClernon D, Florance A, Sall J, Wannamaker P, and Shaefer M for the ACTION study group
 
Background
Abacavir/Lamivudine/Zidovudine (ABC/3TC/ZDV, Trizivir) & Atazanavir (ATV, Reyataz) are alternative options in ARV-naive patients
 
ABC/3TC/ZDV should be reserved for those who cannot receive an NNRTI or PI-based regimen1
 
ATV without ritonavir is an alternative to the preferred PI-based regimen, Lopinavir/ritonavir
 
Both regimens are used in clinical practice in select patient populations as they are well-tolerated and convenient therapies.
 

StudyD-1.gif

STUDY ENDPOINTS
Primary Endpoint

Proportion of subjects with HIV-1 RNA <50 c/mL at Week 48 --Subjects must not have met any definition of virologic failure --ITT-E, Missing/Switch = Failure Analysis
 
Key Secondary Endpoints
Efficacy
--Proportion of subjects with HIV-1 RNA <50 c/mL, switch ≠ failure
--Change in HIV-1 RNA and CD4 cell counts from BL
--Treatment-emergent genotype mutations
Safety
--Drug-related adverse events (Grade 2-4) and serious adverse events Changes in lipid parameters, insulin sensitivity and resistance
 
VIROLOGIC FAILURE CRITERIA
 
Virologic failure was defined as any of the following:
- Failure to have ≥ 1 log HIV-1 RNA drop by Week 12
- Failure to have HIV-1 RNA <400 by Week 24
- Confirmed HIV-1 RNA <50 then ≥ 400 confirmed prior to Week 24
- Confirmed HIV-1 RNA ≥ 400 after Week 24
- HIV-1 RNA ≥ 400 at Week 48 without confirmation
 
*Virologic responders could not have met any virologic failure criteria.

basDem-2.gif

abc-3.gif

median-4.gif

treatEm-5.gif

percent-6.gif

AUTHOR SUMMARY
In an ITT(E) M/S=F analysis, 62% vs. 59% of subjects achieved HIV-1 RNA <50 copies/ml in the overall population (ABC/3TC/ZDV vs. ATV+3TC/ZDV, respectively)
 
Protocol-defined virologic failure occurred in 13% of subjects and were balanced between arms
 
No treatment-emergent primary PI mutations in the ATV+3TC/ZDV arm were observed through 48 weeks and the majority of NRTI mutations were attributed to M184V
 
AUTHOR CONCLUSION
In this study, ABC/3TC/ZDV and ATV+3TC/ZDV were well-tolerated and had comparable efficacy
 
In select patients naive to therapy with HIV-1 RNA <100,000 c/mL, ABC/3TC/ZDV remains a viable option as an initial regimen
 

HIVRNA-7.gif

adverseEvent-8.gif

medianFast-9.gif

toxict-10.gif

HIVVirlog-11.gif

VirRsp-12.gif

Phase IV, randomized, multicenter, open-label study evaluating the safety and efficacy of ABC/3TC/ZDV vs. ATV + 3TC/ZDV in ART-naive subjects over 48 weeks
 
279 subjects were enrolled from 46 sites in the U.S. & Mexico between May 2004 - March 2005.
-- 95% from U.S. sites.
 
Subjects experiencing toxicity from randomized treatment were permitted to switch medications
-- Suspected ABC HSR reaction to 3TC/ZDV + Tenofovir
-- Atazanavir-related jaundice or scleral icterus to Fosamprenavir + 3TC/ZDV
 
Virologic failure was based on multiple criteria

400ml-13.gif

timeLoss-14.gif

subject-15.gif

sub573TZV-16.gif

subjectATV-17.gif

HIVTimeWeek-18.gif